🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lyudmila Bazhenova

University of California San Diego

ORCID: 0000-0001-8764-4359
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Papers

Driven by 12 papers — median percentile 0. Top paper: “Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial”.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0800
N/A
3.5DataRank · unranked
140 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209
N/A
3.1DataRank · unranked
105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study

Targeted Oncology(2023)10.1007/s11523-023-00973-7
N/A
0.434DataRank · unranked
17 citations

Shadera Slatter, Jesse Sussell, Chia-Wei Lin, Sarika Ogale, Debajyoti Datta +4 more

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)

JCO Clinical Cancer Informatics(2023)10.1200/cci.22.00165
N/A
0.336DataRank · unranked
4 citations

Weijia Fan, Aijin Wang, Riha Vaidya, Mary W. Redman, Scott Gettinger +5 more

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9044
N/A
0DataRank · unranked
0 citations

Hsin-Hui Huang, Mary W. Redman, Roy S. Herbst, Scott Gettinger, Lyudmila Bazhenova +15 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003
N/A
0DataRank · unranked
8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9046
N/A
0DataRank · unranked
0 citations

Dzifa Y. Duose, Jiexin Zhang, Mary W. Redman, Rossana Lazcano Segura, Mario L. Marques‐Piubelli +14 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1
N/A
0DataRank · unranked
0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0251
N/A
0DataRank · unranked
42 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Lung Cancer(2024)10.1016/j.lungcan.2024.107928
N/A
0DataRank · unranked
16 citations

Jun Vivien Yin, Penelope A. Bradbury, David J. Kwiatkowski, Shiven B. Patel, Lyudmila Bazhenova +24 more

Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

(2024)10.1158/1078-0432.c.7181344.v1
Top 100%
0DataRank
Top 100%0 citations

Jiexin Zhang, Dzifa Y. Duose, Edgar Gonzalez‐Kozlova, Mary W. Redman, Hong Chen +42 more